Biological Safety Articles & Analysis
34 news found
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics has introduced its efficient and precise Microbial Genome Editing services to support researchers in the modification of specific target genes within an organism's genome.Microbial cell factories are a promising mode of production for fuels, chemicals, and pharmaceuticals because microbial ...
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics has announced the expansion and enhancement of its comprehensive Drug Discovery Services to help scientists advance antiviral therapeutic development, including target selection and validation, hit selection and optimization, and preclinical development. These new services will support ...
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics has announced the launch of its Zika Virus Animal Model services for scientists to understand the complex mechanisms of Zika virus infection and develop effective countermeasures. These models are valuable tools in the research and development of vaccines and therapeutics against this emerging ...
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics is proud to announce the launch of its innovative Influenza A Virus Mouse Models to assess the impact of virus-host interactions. These mouse models can facilitate comprehensive research into the pathogenesis, immune response, and efficacy of antiviral treatments against influenza A infections. ...
Introduction We recently sat down with one of our valued customers, Dr Alexis Rossignol (Clean Cells), to discuss his experience with VIPS PRO, our cutting-edge technology designed to streamline and enhance the early stages of cell line development. This interview provides insight into Clean Cells’ quest to automate and increase single-cell seeding while having undisputable proof ...
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics is proud to announce the launch of its comprehensive portfolio of ELISA Based Assays for vaccine development and bioprocess applications. Vaccine development involves a variety of assays to support vaccine research and development, from early preclinical studies to final production, quality ...
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics has recently announced the launch of its new Checkerboard Assay services to support researchers in evaluating the interaction of two antimicrobial test compounds, including Standard Bacteria Culturing, Antimicrobial Synergy Testing, and Statistics Analysis of experimental results. The ...
TOMI Environmental Solutions, Inc.® ("TOMI") (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced that the Company has entered into a contract with Vizient, Inc. increasing TO Mi's presence in the U.S. healthcare system. Vizient is the largest group purchasing organization (GPO) in the healthcare industry supplying around $100 billion in ...
As an expert in virology and microbiology, Creative Diagnostics recently introduced the Microneutralization Assay Service to support research labs in detecting virus-specific neutralizing antibodies from human and animal sera. Measuring antibody titers against specific viruses is indispensable to virology and several assays have been exploited based on similar principles, i.e., serial dilutions ...
FREDERICK, Md., March 13, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced it will report results for the fourth quarter ended December 31, 2022, after the close of the financial markets on Thursday, March 16, 2023 and will hold a conference call at ...
FREDERICK, Md., Jan. 25, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, announces that TOMI will present its SteraMist brand of products at three upcoming International Society for Pharmaceutical Engineering (ISPE) Conferences in the first quarter of 2023: The ISPE ...
FREDERICK, Md., Jan. 17, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, announces that the National Health Services (NHS) Wales purchased SteraMist ionized Hydrogen Peroxide (iHP) technology further expanding presence in Great Britain. NHS Wales is a publicly funded ...
As an expert in the antiviral field providing solutions to assist virology and microbiology research, Creative Diagnostics recently introduced Fluorometric Neuraminidase Assay services to the global research community, suitable for functional detection of NI-resistant viruses in mixed virus populations and monitoring the neuraminidase activity of non-viral or bacterial origin. Neuraminidase ...
As a consulting and experimental service provider specializing in virology and microbiology, Creative Diagnostics recently introduced CC50/IC50 Assay service with a high level of assay sensitivity and accuracy. The CC50 and IC50 will be plotted using a sigmoidal dose-response curve, and the selectivity index (SI) for each compound is estimated by dividing the CC50 with the IC50. Pharmaceutical ...
CD ComputaBio, a reliable computational biology service provider located in New York, is always hammering away at research and trials in order to provide customers with access to the latest software, technologies, and expertise at a competitive price and fast turnaround time. The company recently announced the launch of PD-L1 targeting service for cancer research. Over the past decade, ...
Aclys utilizes a proprietary set of patient molecular data to select differentiated targets and create precision biologics with the safety profile and response rates only achievable with precision biologics. About Aclys Bio Aclys Bio discovers and develops precision biologics for the treatment of cancer. Aclys has identified a ...
Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. ...
COVAXIN™ whole virus inactivated vaccine generated broad antibody response comparable to those seen in a large phase 3 trial in adults 18+ Adverse events were primarily mild, and no serious adverse events (SAEs) were noted Immunobridging trial demonstrated safety, reactogenicity and immunogenicity of COVAXIN™ in children from 2 years old and up No cases of ...
Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. ...
ISM001-055 is a potentially first-in-class small molecule inhibitor of a novel biological target discovered by Pharma.AI, Insilico Medicine's end-to-end AI-powered drug discovery platform. ...